Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.
Expert oncologists who treat patients with advanced RCC discuss updates from clinical trials presented during the 2023 European Society for Medical Oncology Congress that further defined the treatment paradigm in advanced RCC and gave a peek into the potential future of the disease management.
The Food and Drug Administration has approved Welireg for patients with advanced renal cell carcinoma, a type of kidney cancer, following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.